Search Within

Andrew Michael Intlekofer

Formats
  1. Meeting Abstract (51)
  2. Journal Article (37)
  3. Review (4)
  4. Book Section (2)
  5. Editorial (2)
  6. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (98)
  2. Department of Medicine (98)
  3. GSK Faculty (98)
  4. Hematologic Malignancies Research (98)
  5. Hematologic Malignancies, Division of (98)
  6. Human Oncology and Pathogenesis Program (98)

More Groups

People
  1. Andrew Zelenetz (47)
  2. Maria Palomba (45)
  3. Steven Horwitz (44)
  4. Alison Moskowitz (41)
  5. Anita Kumar (41)
  6. Ariela Noy (41)

More People

Years
  1. 2025 (5)
  2. 2024 (12)
  3. 2023 (14)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (6)

More Years

Publications
  1. Blood (43)
  2. Blood Advances (3)
  3. Cancer Discovery (3)
  4. Cancer Research (3)
  5. Cell Metabolism (3)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. Nature Publishing Group (13)
  3. American Association for Cancer Research (6)
  4. Cell Press (4)
  5. Elsevier Inc. (4)
  6. American Society of Clinical Oncology (3)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity
    Journal Article

    Holling, G. A.; Chavel, C. A.; Sharda, A. P.; Lieberman, M. M.; James, C. M.; Lightman, S. M.; Tong, J. H.; Qiao, G.; Emmons, T. R.; Giridharan, T.; more...
    Cellular & Molecular Immunology (2024)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save